Best Practices for Building High-Impact Patient Advocacy Partnerships in Pharma
CHAPEL HILL, N.C., Feb. 21, 2025/ --In today’s evolving healthcare landscape, patient advocacy partnerships have become a crucial pillar for pharma companies aiming to enhance patient engagement and education. Organizations are refining their advocacy models to align with regulatory expectations, digital outreach, and long-term collaboration goals.
Best Practices, LLC has released a benchmarking study titled "Patient Advocacy: How Top Pharma Manufacturers Effectively Support Advocacy Groups Segmented by Reporting Function," which provides key insights from 63 industry leaders across 49 biopharma organizations.
The report delves into key areas such as:
- Effective practices for working with patient advocacy groups
- Preferred advocacy structures and tools
- Core competencies of advocacy professionals
- Lessons learned from socially sensitive or stigmatized disease areas
- Emerging trends shaping the future of manufacturer-advocacy collaboration
According to the study, collaborations with patient advocacy groups are most impactful during the pre-launch and launch stages. As patient advocacy evolves, 73% of companies follow a centralized model for patient advocacy engagement, ensuring alignment across teams. Additionally, companies are increasingly leveraging real-world patient insights and digital strategies to improve outreach and impact. The most important platforms for delivering education to patient groups are Facebook and YouTube, along with other video sites.
This research equips biopharma leaders with actionable strategies to optimize their advocacy efforts and foster meaningful patient partnerships.
For a deeper dive, download the complimentary report summary here: https://www.best-in-class.com/rw443.htm
Pressed for time? Watch the short video summary of the key insights: